<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03740048</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00054726</org_study_id>
    <nct_id>NCT03740048</nct_id>
  </id_info>
  <brief_title>A Pilot Trial of Twice-weekly Versus Thrice-weekly Hemodialysis in Patients With Incident End-stage Kidney Disease</brief_title>
  <acronym>TWOPLUS-HD</acronym>
  <official_title>A Randomized Pilot Study of Hemodialysis Initiation Comparing Twice-Weekly Hemodialysis Plus Dialysis-Sparing Therapy Versus Thrice-Weekly Hemodialysis (The TWOPLUS-HD Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The optimal frequency of hemodialysis treatments in patients with incident end-stage kidney
      disease in not known. This pilot trial will randomize patients with incident end-stage kidney
      disease due to chronic kidney disease progression to two different regimens of hemodialysis:
      i) twice-weekly hemodialysis for six weeks with adjuvant pharmacologic medications followed
      by thrice-weekly hemodialysis, or ii) thrice-weekly hemodialysis. The study will test
      feasibility of stepwise hemodialysis, and the effects of the two regimens of hemodialysis on
      residual kidney function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2019</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Recruitment will be determined as the proportion of people meeting inclusion criteria who ultimately consent to randomization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Protocol Adherence</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Protocol adherence will be determined as the proportion of participants who abide to the HD schedule, including transition from twice-weekly to thrice-weekly HD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in residual kidney function</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Residual renal urea clearance (Krt/Vurea) will be calculated at baseline and after HD initiation (week 6 and week 12) as clearance per minute excretion of urea nitrogen using time-averaged serum water urea nitrogen concentration during the urine collection period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Solute clearance</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Monthly spKt/Vurea and stdKt/Vurea in the first quarter of hemodialysis will be compared between the two treatment groups. Total stdKt/Vurea will be calculated by adding residual renal urea clearance (Krt/Vurea ) (i.e., stdKt/Vurea month 1 will include baseline Krt/Vurea; stdKt/Vurea month 2 will include Krt/Vurea based on inter-dialytic urine collection performed during week 6; stdKt/Vurea month 3 will include Krt/Vurea performed during week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Events of hyperkalemia</measure>
    <time_frame>up to 24 months</time_frame>
    <description>The rate of hyperkalemia events (serum potassium ≥5.5mEq/L on inter-dialytic day or ≥6.0mEq/L pre-HD on dialysis day) in the first 12 weeks of hemodialysis will be compared between the two study groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume Management</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Volume management will be compared between study groups as proportion of markers of volume overload in the first 12 weeks of hemodialysis. Surrogate markers of volume overload will include: inter-dialytic weight gain &gt;2.5kg, relative inter-dialytic weight gain &gt;5.7% of the target weight, and ultrafiltration rate &gt;10ml/kg/hr.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Events of metabolic acidosis</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Metabolic acidosis will be classified as serum bicarbonate ≤22mEq/L on inter-dialytic day or ≤20mEq/L pre-HD on dialysis day. The rate of metabolic acidosis in the first 12 weeks of hemodialysis will be compared between the two study groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first hospitalization</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Time to first hospitalization (in days) from first outpatient HD treatment will compared between treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization Rate</measure>
    <time_frame>up to 24 months</time_frame>
    <description>The hospitalization rate will be compared in the first 12 weeks of hemodialysis between the two treatment groups and expressed per 100 patient-days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Quality of Life- KDQOL-SF36 questionnaire</measure>
    <time_frame>up to 24 months</time_frame>
    <description>The Kidney Disease Quality of Life (KDQOL-SF36) questionnaire is a short form that measures the burden of kidney disease, symptoms/problems of kidney disease, and effects of kidney disease scales. The score range is 0-100 with higher scores denoting better outcomes.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Long-term change in residual kidney function</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Residual renal urea clearance (Krt/Vurea) will be calculated based on inter-dialytic urine collection at week 24 and week 48 of hemodialysis. The change in Krt/Vurea from baseline will be compared between the two treatment arms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Survival</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Exploratory analyses will compare the mortality rate between the two schedules of hemodialysis at week 12, week 24 and week 48 after dialysis initiation.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">202</enrollment>
  <condition>End Stage Renal Failure on Dialysis</condition>
  <arm_group>
    <arm_group_label>Hemodialysis and Pharmacologic Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemodialysis regimen at the initiation of dialysis treatment: Twice-weekly hemodialysis plus adjunctive pharmacologic therapy (loop diuretic, potassium-binding agent, and sodium bicarbonate) for six consecutive weeks, continued by thrice-weekly hemodialysis (intervention group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Hemodialysis Regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hemodialysis regimen at the initiation of dialysis treatment: thrice-weekly hemodialysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hemodialysis</intervention_name>
    <description>Hemodialysis frequency will differ in the first six weeks of hemodialysis therapy between the two treatment arms.</description>
    <arm_group_label>Conventional Hemodialysis Regimen</arm_group_label>
    <arm_group_label>Hemodialysis and Pharmacologic Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patiromer Oral Product</intervention_name>
    <description>Participants in the intervention group who develop hyperkalemia, during the first six weeks of receiving hemodialysis twice per week, will be treated with Patiromer.</description>
    <arm_group_label>Hemodialysis and Pharmacologic Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  Incident ESKD from CKD progression (including a failing renal transplant)

          -  Are deemed to require dialysis initiation by the treating nephrologist

          -  Have elected HD for renal replacement therapy (RRT)

        Exclusion Criteria:

          -  Have urine output &lt;500ml per day

          -  Have ESKD as a result of severe acute kidney injury (AKI) (stage 3 AKI defined by
             Acute Kidney Injury Network [AKIN]) criteria)

          -  Abrupt decline in kidney function preceding HD therapy initiation (i.e., if eGFR was
             ≥30 mL/min/1.73 m2 3 months prior to the initiation of dialysis therapy)

          -  Are scheduled to undergo transplantation from a live donor within the next 6 months

          -  Have an active diagnosis of hepatorenal syndrome

          -  Have a significant malignancy that is likely to impact survival

          -  Have a medical condition that would jeopardize the safety of the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariana Murea, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carrie Smith</last_name>
    <phone>3367137531</phone>
    <email>suscmit@wakehealth.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mariana Murea, MD</last_name>
    <phone>3367162074</phone>
    <email>mmurea@wakehealth.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Smith</last_name>
      <phone>336-713-7531</phone>
      <email>suscmit@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mariana Murea, MD</last_name>
      <phone>3367162074</phone>
      <email>mmurea@wakehealth.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>National Kidney Foundation. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 update. Am J Kidney Dis. 2015 Nov;66(5):884-930. doi: 10.1053/j.ajkd.2015.07.015. Review. Erratum in: Am J Kidney Dis. 2016 Mar;67(3):534.</citation>
    <PMID>26498416</PMID>
  </reference>
  <reference>
    <citation>Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study. N Engl J Med. 1981 Nov 12;305(20):1176-81.</citation>
    <PMID>7027040</PMID>
  </reference>
  <reference>
    <citation>Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R; Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002 Dec 19;347(25):2010-9.</citation>
    <PMID>12490682</PMID>
  </reference>
  <reference>
    <citation>Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S; Mexican Nephrology Collaborative Study Group. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol. 2002 May;13(5):1307-20.</citation>
    <PMID>11961019</PMID>
  </reference>
  <reference>
    <citation>Lo WK, Ho YW, Li CS, Wong KS, Chan TM, Yu AW, Ng FS, Cheng IK. Effect of Kt/V on survival and clinical outcome in CAPD patients in a randomized prospective study. Kidney Int. 2003 Aug;64(2):649-56.</citation>
    <PMID>12846762</PMID>
  </reference>
  <reference>
    <citation>Li Y, Jin Y, Kapke A, Pearson J, Saran R, Port FK, Robinson BM. Explaining trends and variation in timing of dialysis initiation in the United States. Medicine (Baltimore). 2017 May;96(20):e6911. doi: 10.1097/MD.0000000000006911.</citation>
    <PMID>28514305</PMID>
  </reference>
  <reference>
    <citation>Chin AI, Appasamy S, Carey RJ, Madan N. Feasibility of Incremental 2-Times Weekly Hemodialysis in Incident Patients With Residual Kidney Function. Kidney Int Rep. 2017 Jun 21;2(5):933-942. doi: 10.1016/j.ekir.2017.06.005. eCollection 2017 Sep.</citation>
    <PMID>29270499</PMID>
  </reference>
  <reference>
    <citation>Lin YF, Huang JW, Wu MS, Chu TS, Lin SL, Chen YM, Tsai TJ, Wu KD. Comparison of residual renal function in patients undergoing twice-weekly versus three-times-weekly haemodialysis. Nephrology (Carlton). 2009 Feb;14(1):59-64. doi: 10.1111/j.1440-1797.2008.01016.x. Epub 2008 Nov 19.</citation>
    <PMID>19019171</PMID>
  </reference>
  <reference>
    <citation>Zhang M, Wang M, Li H, Yu P, Yuan L, Hao C, Chen J, Kalantar-Zadeh K. Association of initial twice-weekly hemodialysis treatment with preservation of residual kidney function in ESRD patients. Am J Nephrol. 2014;40(2):140-50. doi: 10.1159/000365819. Epub 2014 Aug 23.</citation>
    <PMID>25171342</PMID>
  </reference>
  <reference>
    <citation>Shafi T, Jaar BG, Plantinga LC, Fink NE, Sadler JH, Parekh RS, Powe NR, Coresh J. Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. Am J Kidney Dis. 2010 Aug;56(2):348-58. doi: 10.1053/j.ajkd.2010.03.020. Epub 2010 Jun 3.</citation>
    <PMID>20605303</PMID>
  </reference>
  <reference>
    <citation>Termorshuizen F, Dekker FW, van Manen JG, Korevaar JC, Boeschoten EW, Krediet RT; NECOSAD Study Group. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol. 2004 Apr;15(4):1061-70.</citation>
    <PMID>15034110</PMID>
  </reference>
  <reference>
    <citation>Marquez IO, Tambra S, Luo FY, Li Y, Plummer NS, Hostetter TH, Meyer TW. Contribution of residual function to removal of protein-bound solutes in hemodialysis. Clin J Am Soc Nephrol. 2011 Feb;6(2):290-6. doi: 10.2215/CJN.06100710. Epub 2010 Oct 28.</citation>
    <PMID>21030575</PMID>
  </reference>
  <reference>
    <citation>Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B; OPAL-HK Investigators. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015 Jan 15;372(3):211-21. doi: 10.1056/NEJMoa1410853. Epub 2014 Nov 21.</citation>
    <PMID>25415805</PMID>
  </reference>
  <reference>
    <citation>Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA; AMETHYST-DN Investigators. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. JAMA. 2015 Jul 14;314(2):151-61. doi: 10.1001/jama.2015.7446. Erratum in: JAMA. 2015 Aug 18;314(7):731. Dosage error in article text.</citation>
    <PMID>26172895</PMID>
  </reference>
  <reference>
    <citation>Pitt B, Bakris GL, Bushinsky DA, Garza D, Mayo MR, Stasiv Y, Christ-Schmidt H, Berman L, Weir MR. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. 2015 Oct;17(10):1057-65. doi: 10.1002/ejhf.402. Epub 2015 Oct 12.</citation>
    <PMID>26459796</PMID>
  </reference>
  <reference>
    <citation>Kovesdy CP, Regidor DL, Mehrotra R, Jing J, McAllister CJ, Greenland S, Kopple JD, Kalantar-Zadeh K. Serum and dialysate potassium concentrations and survival in hemodialysis patients. Clin J Am Soc Nephrol. 2007 Sep;2(5):999-1007. Epub 2007 Aug 16.</citation>
    <PMID>17702709</PMID>
  </reference>
  <reference>
    <citation>Wu DY, Shinaberger CS, Regidor DL, McAllister CJ, Kopple JD, Kalantar-Zadeh K. Association between serum bicarbonate and death in hemodialysis patients: is it better to be acidotic or alkalotic? Clin J Am Soc Nephrol. 2006 Jan;1(1):70-8. Epub 2005 Nov 23.</citation>
    <PMID>17699193</PMID>
  </reference>
  <reference>
    <citation>Daugirdas JT. Estimating Time-averaged Serum Urea Nitrogen Concentration during Various Urine Collection Periods: A Prediction Equation for Thrice Weekly and Biweekly Dialysis Schedules. Semin Dial. 2016 Nov;29(6):507-509. doi: 10.1111/sdi.12554. Epub 2016 Oct 4.</citation>
    <PMID>27699876</PMID>
  </reference>
  <reference>
    <citation>Daugirdas JT, Depner TA, Greene T, Levin NW, Chertow GM, Rocco MV; Frequent Hemodialysis Network Trial Group. Standard Kt/Vurea: a method of calculation that includes effects of fluid removal and residual kidney clearance. Kidney Int. 2010 Apr;77(7):637-44. doi: 10.1038/ki.2009.525. Epub 2010 Jan 27.</citation>
    <PMID>20107428</PMID>
  </reference>
  <reference>
    <citation>Jansen MA, Hart AA, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT; NECOSAD Study Group. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int. 2002 Sep;62(3):1046-53.</citation>
    <PMID>12164889</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 9, 2018</study_first_submitted>
  <study_first_submitted_qc>November 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <keyword>Kidney Disease</keyword>
  <keyword>Kidney Function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After study completion, de-identified participant data may be provided to other researchers in the filed if requested. The request(s) will be reviewed by the principal investigator and other study members to determine if appropriate.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>2-4 months</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

